Immediate Impact Profile: Nasdaq Breakout Idea (HUGE) Has 4 Potential Catalysts To Scope Now

Oh, man, what a time to be alive! Immediate Impact Profile: Nasdaq Breakout Idea (HUGE) Has 4 Potential Catalysts To Scope Now April 21st Dear Reader, Oh, man, what a time to be alive! You got the NCAA championships and then you got The Masters. And then you got my last Friday alert. Wait a second. Your last Friday alert? What are you talking about? I'm talking about the Nasdaq profile I identified right after 9:30am on Friday morning. Simply put, it shook the markets when it took off like a rocket! When all was said and done, the profile made an approximate intraday surge of 35% from my alerted price around $2.75 after it reached a high of Day of $3.73. Trust me. It was something to marvel at, but there's no time to rest with a new week ahead of us. Let's start getting locked in right now. Here comes a new breakout idea in the form of a Nasdaq Biotech aiming for multi-sector disruption. [There's huge news]( including a recent announcement of expanding this company's pipeline through investigations into weight loss and liver health ingredients and supplements... There's a relatively [low float]( which means volatility will need to be on watch... There's [oversold technicals]( suggesting a major reversal/bounce could be nearing... And when you see these 2 analyst price targets, you'll know it's the top profile that to have on radar come Monday morning. Drop everything and pull up: *FSD Pharma Inc. (HUGE)* FSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. And right now, HUGE has several potential catalysts capable of providing a breakout spark. Check these out: #1. Two Separate Analyst Targets Suggest Wild Upside Potential From Friday's Close. #2. Oversold Technicals May Signal The Coming Of A Mega-Bounce/Healthy Reversal. #3. HUGE Expands Investigative Pipeline To Become Disruptors In The Weight Loss And Liver Health Markets. #4. A Low Float Could Create A Volatile, Must-Watch Scenario In A Blink. But more on those in a second... UNBUZZD™ - Mental Alertness & Detoxification when Alcohol is Consumed What is UNBUZZD™ in a Nutshell? UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. Small focus group research indicates UNBUZZD™ reduces BrAC faster than what the body would do naturally. Clinical trials are being planned for further validation. The active ingredients in UNBUZZD™’s formula help restore mental alertness post-alcohol consumption in an average of about 15-30 minutes. Greater Purpose Today’s recovery drinks have one goal: to relieve undeniable discomfort after a night out of drinking, infamously known as the “hangover.” UNBUZZD™ is more than a hangover cure product. The company's purpose is to re-shape the paradigm by taking an innovative approach to reduce the burden of the aftermath effects of excess alcohol consumption on society. In short, they understand that one person’s inebriation can impact countless others. UNBUZZD™ turns the time in your favor. Their formulation was curated through scientific research to expedite recovery from inebriation and to accelerate ethanol metabolism in your body, potentially eliminating any performance concerns today or tomorrow. FSD Pharma (NASDAQ: HUGE), the parent company proposing to spin out UNBUZZD™ development through a new subsidiary, is planning human trials to clinically validate this method of action, which would represent a potential industry breakthrough. Two distinct markets can be served with this technology: 1. Consumer Market (UNBUZZD™) – enjoy alcohol responsibly, work-to-life balance. 2. Hospital Market (REKVRY™) – help an unmet need in the ER and other healthcare settings, reducing costs and burden on healthcare resources/staff. Market Opp. There has yet to be a product backed by strong clinical data that targets reducing BAC (BrAC) levels and Mental Alertness, directly and efficiently. UNBUZZD™ is MORE THAN Hangover Cure Products. Global Hangover Cure Products market size was valued at $1.56Bn in 2020 and expected to expand at a CAGR of 14.6% from 2021 to 2028 (Consumer, 2021). LUCID-MS: Patented new chemical entity (NCE) Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models. LUCID-MS: Disease Modifying Enabling Remyelination A sampling of the novel qualities of Lucid-MS include: - Excellent efficacy in various preclinical animal models - Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation - Does not suppress immune system (non-immunomodulatory) - Potential oral administration with easy dosing regimen FSD Pharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS. Today there is no cure for Multiple Sclerosis. FSD Pharma (“HUGE”) is trying to change this for millions of people. [Read more about the company here.]( ----- (Nasdaq: HUGE): 4 Potential Breakout Catalysts To Focus On Immediately #1. Two Separate Analyst Targets Suggest Wild Upside Potential From Friday's Close. The headline says it. HUGE has 2 major analyst targets suggesting massive upside potential. In fact, from Friday's close, a [Goldman Small Cap Research]( report provides a $4.60 target implying a potential upside of over 800%! Here's some report highlights: - The two lead product candidates in HUGE’s two business lines, which represent unmet needs, are poised to achieve substantial growth and market penetration. HUGE will commence commercialization in early 2024 in one business line and launch a 2H24 Phase II clinical trial in the other. - Our 12-month price target of $4.60 is based on the future value of the UNBUZZD™ business, and a NPV estimate of the Lucid-MS product. These forecasts are based on projected sales of UNBUZZD™ and Lucid-MS. And then there's a $6.00 target from [Singular Research]( suggesting upside potential well over 1,000%! Here's some report highlights: - FSD Pharma’s functional beverage drink, Unbuzzd™ is targeting to address the huge unmet need for accelerating alcohol metabolism to quickly restore mental alertness. The market opp. is very large and HUGE stands to benefit significantly once the product reaches the commercial stage (expected by Q1:24). ----- #2. Oversold Technicals May Signal The Coming Of A Mega-Bounce/Healthy Reversal. Here's what was cooking at 4:00PM EST Friday. [Barchart]( was reporting multiple oversold technical indicators for HUGE. These technicals could be signaling a healthy reversal is approaching in the near term. Here's the definition of a "reversal" from [Investopedia]( "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here's the technicals to pay close attention to (as of close Friday): - 9-Day Relative Strength Index: 13.39% - 14-Day Relative Strength Index: 18.39% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. - 14-Day Raw Stochastic: 17.11% - 14-Day Williams %R: 82.89% As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. #3. HUGE Expands Investigative Pipeline To Become Disruptors In The Weight Loss And Liver Health Markets. FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), ..., announced the expansion of its pipeline into metabolic and related disorders including weight loss and liver health. The Company has initiated investigations into ingredients and dietary supplements that may have the potential to promote weight loss and liver health. The Company is already pursuing products to promote faster alcohol metabolism and ameliorate the effects of acute alcohol intoxication. The Company is investigating certain ingredients and combinations of ingredients that show promise in improving liver health, reducing metabolic disease, and reducing visceral fat which could lead to weight loss and liver health. The Company is pursuing this pipeline to potentially create a new exciting product line in addition to unbuzzd™. [Read the full article here.]( #4. A Low Float Could Create A Volatile, Must-Watch Scenario In A Blink. According to the [Yahoo Finance]( website, HUGE has a relatively low(ish) float. The website reports this profile to have approximately 34.34Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news early in 2024 provide a near term spark? ----- HUGE Recap - 4 Potential Breakout Catalysts To Know #1. Two Separate Analyst Targets Suggest Wild Upside Potential From Friday's Close. #2. Oversold Technicals May Signal The Coming Of A Mega-Bounce/Healthy Reversal. #3. HUGE Expands Investigative Pipeline To Become Disruptors In The Weight Loss And Liver Health Markets. #4. A Low Float Could Create A Volatile, Must-Watch Scenario In A Blink. ----- Coverage is officially initiated on (Nasdaq: HUGE). Get it on your radar now! Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc-laim-er here: [www.stockwirenews.net/disclosure]( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 4/21/24 and ending on 4/22/24 to publicly disseminate information about (HUGE) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (HUGE). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Awareness Consulting Network, TD Media LLC has been hired for a period beginning on 04/21/2024 and ending on 04/22/2024 to publicly disseminate information about (HUGE:US) via digital communications. We have been paid thirty thousand dollars USD to disseminate information about (HUGE:US) via digital communications. We own zero shares of (HUGE:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.ccsend.com